Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is unsettled, but we do plan to promenade with an “unofficial” mascot because we are canine-sitting for a few days. Otherwise, we hope to hang with a short person or two and catch up on our reading. And what about you? This may be a good time to pursue activities that promote calm, given recent events. Or you could instead indulge your impulses and go Armageddon shopping. But remember what Chicken Little said when told the sky was falling? “Sell sky,” was the reply. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.

Health and Human Services Secretary Alex Azar testified that the Trump administration is open to Medicare negotiation of drug prices, Inside Health Policy tells us. Just last week, Azar said the president’s proposed budget supports a Senate Finance Committee drug pricing bill, which specifically does not include pricing negotiations. “We are open to that, but it has to be practical and implementable,” Azar told House Ways & Means Chair Richard Neal (D-Mass.) when asked whether the administration supports government price negotiation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.